Exploring the Potential of Monoclonal Antibody Therapeutics for HIV-1 Eradication

The HIV field has seen an increased interest in novel cure strategies. In particular, new latency reversal agents are in development to reverse latency to flush the virus out of its hiding place. Combining these efforts with immunotherapeutic approaches may not only drive the virus out of latency, but allow for the rapid elimination of these infected cells in a shock and kill approach. Beyond cell-based approaches, growing interest lies in the potential use of functionally enhanced killer monoclonal therapeutics to purge the reservoir. Here we discuss prospects for a monoclonal therapeutic-based shock and kill strategy that may lead to the permanent elimination of replication-competent virus, making a functional cure a reality for all patients afflicted with HIV worldwide.